Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals ...

DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

There are five projects from Tullamore College. 'Perimenopause Uncovered: Empowering women through knowledge' was entered by ...

He also articulated a very specific doctrine about the role of an FDA commissioner, one that is limited in its power and ...

"The Republican Party will not cut benefits," Republican House Speaker Mike Johnson said. Also in the news: Medicare drug price negotiations, the House transgender bathroom ban, and more.

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

The current opportunity stemmed from a shortage, a loophole allowing compounded generic alternatives when a patented product isn't available to patients. Hims & Hers sells compounded semaglutide ...